Entecavir NDC 16714-717

NDC codes

FDA NDC Directory

Product NDC (as listed)16714-717Labeler and product segments. Claims need a package NDC.

Product NDC at billing width16714-0717Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
16714-717-01	16714071701	30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (16714-717-01)Marketed from Jun 15, 2017

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Entecavir
Generic name (nonproprietary): entecavir
Active ingredients: Entecavir — .5 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: NorthStar RxLLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 206872
Marketing start: Jun 15, 2017
Listing expires: Dec 31, 2027
Other FDA classes: Nucleoside Analog (EXT)Nucleoside Reverse Transcriptase Inhibitors (Mechanism)
Identifiers: Product ID 16714-717_3e6a4c6c-0a9e-4ffd-b8e0-853bbfa961a9SPL ID 3e6a4c6c-0a9e-4ffd-b8e0-853bbfa961a9SPL set ID da705339-c349-444f-a058-4f0cef2864bfRxCUI 485434, 485436UNII 5968Y6H45M
Pharmacologic class: Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N416714071701 followed by a unit qualifier and the quantity

Package 16714-0717-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 7, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Entecavir tablet is a hepatitis B virus nucleoside analogue reverse transcriptase inhibitor indicated for the treatment of chronic hepatitis B virus infection in adults and children at least 2 years of age with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. ( 1 ) Entecavir tablet is indicated for the treatment of chronic hepatitis B virus infection in adults and pediatric patients 2 years of age and older with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 206872

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 206872
Product	Strength	Form · route	Labeler	Product NDC
Entecavir	Entecavir 1 mg/1	Tablet, Film coatedOral	NorthStar RxLLC	16714-718
Entecavir	Entecavir 1 mg/1	Tablet, Film coatedOral	Cipla USA Inc.	69097-425
Entecavir	Entecavir .5 mg/1	Tablet, Film coatedOral	Cipla USA Inc.	69097-426